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INHIBITION OF HEPARANASE ACTIVITY AND HEPARANASE-INDUCED
ANGIOGENESIS BY SURAMIN ANALOGUES
Dario MARCHETTI*, Jane REILAND, Brad ERWIN and Madhuchhanda ROY
Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, USA
Heparanase, a heparan sulfate-specific endo--D-glucuron-
idase, plays an important role in tumor cell metastasis
through the degradation of extracellular matrix heparan sul-
fate proteoglycans (ECM HSPG). Heparanase activity corre-
lates with the metastatic propensity of tumor cells. Suramin,
a polysulfonated naphthylurea, is an inhibitor of heparanase
with suramin analogues shown to possess antiangiogenic and
antiproliferative properties. We investigated the effects of
selected suramin analogues (NF 127, NF 145 and NF 171) on
heparanase activity and heparanase-driven angiogenesis.
Studies of the ability of cellular extracts and purified hepara-
nase from human, highly invasive and brain-metastatic mel-
anoma (70W) cells revealed that heparanase expressed by
these cells was effectively inhibited by suramin analogues in a
dose-dependent manner. These analogues possessed more
potent heparanase inhibitory activities than suramin: The
concentrations required for 50% heparanase inhibition (IC50)
were 20–30 M, or at least 2 times lower than that for
suramin. One hundred percent inhibition was observed at
concentrations of 100 M and higher. Of relevance, these
compounds significantly decreased (i) the invasive capacity of
human 70W cells by chemoinvasion assays performed with
filters coated with purified HSPG or Matrigel™, and (ii) blood
vessel formation by in vivo angiogenic assays, thus linking
their antiangiogenic properties with impedance of hepara-
nase-induced angiogenesis. Specifically, inhibition of invasion
by NF 127, NF 145 and NF 171 was found at 10 M concen-
trations of compounds with a significant decrease of invasive
values at concentrations as low as 1.5 M. In addition, NF
127, NF 145 and NF 171 promoted nearly complete inhibi-
tion of heparanase-induced angiogenesis at values ranging
from 236 M (for NF 145) to 362 M (for NF 127). These
results further emphasize the importance of heparanase in
invasive and angiogenic mechanisms and the potential clini-
cal application of heparanase inhibitors such as suramin an-
alogues in cancers and angiogenesis-dependent diseases.
© 2003 Wiley-Liss, Inc.
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Tumor cell-mediated degradation of heparan sulfate proteogly-
cans (HSPG) in basement membranes (BM) or extracellular matrix
(ECM) has been demonstrated.1–3 Cleavage of HS results in dis-
assembly of subendothelial ECM and hence may play a decisive
role in extravasation of blood-borne cells. Among the cellular
enzymes involved in BM/ECM degradation is an endo--D-glu-
curonidase called heparanase that cleaves HS at specific intrachain
sites.1,3–5 Expression of heparanase correlates with the metastatic
potential of tumor cells4,6–8 and with the ability of activated cells
of the immune system to leave the circulation and elicit both
inflammatory and autoimmune responses.3,6 Elevated heparanase
levels have been detected in metastatic cancer cells, in sera from
metastatic tumor-bearing animals, in tumor biopsies of cancer
patients and in the urine of patients with aggressive metastatic
disease.1,6 Although these phenomena are well documented, it has
taken 25 years to isolate the heparanase gene. Recently, several
groups have concomitantly reported the successful isolation and
cloning of human heparanase as the first cloning example of a
mammalian HS-degradative enzyme.9–12 The isolated cDNA se-
quences derived from normal (human placenta, platelets) or met-
astatic cells represent the same gene (hpa-1). A gene homologue to
hpa-1, named hpa-2, has also been reported.13 Alternative splicing
of the hpa-2 transcript yielded 3 different mRNAs (hpa-2a,b,c),
encoding putative proteins of 480, 534 and 592 amino acids,
respectively. However, these proteins have neither been isolated
nor functionally studied for heparanase-like enzymatic activity.13
Angiogenesis is critical for the growth of solid tumors and
development of metastases. A number of factors have been linked
to the angiogenic response including proangiogenic cytokines,
angiogenesis modulators and growth factors.14,15 Of importance,
ECM HSPG are directly involved in angiogenesis by serving as a
reservoir for potent angiogenic factors (basic fibroblast growth
factor [bFGF], vascular endothelial growth factor [VEGF] and
others) that can be extracted from ECM produced in vitro.16,17
Therefore, heparanase can be relevant in both invasive (ECM
HSPG degradation) and angiogenic (angiogenic factors mobiliza-
tion from ECM HSPG) events.
Several chemotherapeutic drugs have been analyzed for their
potential as antiangiogenic agents including suramin, a polysul-
fonated naphthylurea. Suramin has been studied as an antineoplas-
tic agent for adrenal cortical malignancies, prostate carcinoma and
lymphoma.18,19 Although the exact mechanism of suramin’s anti-
neoplastic activity is not known, it has been shown to nonspecifi-
cally inhibit the binding of a number of growth factors and inter-
fere with the glycosaminoglycan catabolism, which is associated
with cell proliferation.20,21 Suramin has also been shown to inhibit
angiogenesis and heparanase by independent groups.22,23
The clinical use of suramin has been limited by its toxicity.
Consequently, suramin analogues have been developed with
equivalent or better antitumor activity and less toxicity.24,25 A
number of suramin analogues have been synthesized possessing
antiproliferative effects on tumor cells in vitro and angiostatic
effects on embryologic angiogenesis in vivo.24,26
We investigated the antiheparanase and antiheparanase-angio-
genic effects of a selected group of newly developed suramin
analogues and potent angiogenic inhibitors: NF 127, NF 145 and
NF 171. Here we demonstrate that these suramin analogues (i)
inhibit heparanase-mediated degradation of subendothelial ECM;
(ii) inhibit heparanase itself; (iii) possess higher heparanase inhib-
itory activities than suramin. Of equal importance, we report that
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ton, KY). The analogues were generated in the laboratory of Dr.
Peter Nickel and coworkers (Pharmaceutical Institute, University
of Bonn, Bonn, Germany).24 Their molecular weight, chemical
structure and antiangiogenic properties have been reported.25–27
Cells and tissue culture
Early passage human brain-metastatic melanoma cells (70W
line) were maintained as monolayer cultures in a 1:1 (v/v) mixture
of Dulbecco’s modified Eagle’s medium and Ham’s F-12 nutrient
medium (DMEM/F-12; GIBCO, Grand Island, NY) supplemented
with 5% heat-inactivated fetal bovine serum (FBS; Hyclone Lab-
oratories, Logan, UT).7 Human 70W cells were chosen as a source
of heparanase because they are highly invasive and produce the
enzyme at elevated levels vs. parental MeWo.7,28 Murine brain
endothelial (MBE) cells were grown in dishes coated with gelatin
(0.5%) and containing DMEM/F12 plus 5% FBS and 50 g/ml
endothelial cell growth factor (ECGF; Biomedical Technologies,
Stoughton, MA) reconstituted in DMEM/F-12/1% FBS.29 Upon
reaching confluency, the cells were split with trypsin (0.25%)-
EDTA at an optimal ratio of 1:4. Human RL95 cells were grown
in 1:1 (v/v) DMEM/F12 supplemented with 10% FBS (v/v).28 The
RL95 cell line, an adenocarcinoma of the uterus, was chosen as a
source of HS because of the specific heparanase degradation of
cell-associated HS from this cell line and because  95% of the
glycosaminoglycans (GAG) chains made by these cells is HS.28–30
The [35S]HS labeling required the use of a special medium that
was sulfate depleted (RPMI 1640, Invitrogen Life Technologies,
Carlsbad, CA). Cell lines were periodically checked for Myco-
plasma contamination (Geneprobe kit; San Diego, CA) and only
Mycoplasma-free cell lines were used in our study.
Cell growth analysis
A fluorescence cell viability assay was used for the cell growth
studies. Briefly, 70W cells (1  104) were seeded in each well of
48-multiwell tissue culture plates and cultured in 0.5 ml of
DMEM/F-12 plus 5 g/ml insulin, 5 g/ml transferrin and 25 nM
sodium selenite. After incubation in absence or presence (up to 200
M) of suramin or NF 127, NF 145 and NF 171, respectively, cells
were rinsed with 1,000 volumes of tissue-culture-grade Dulbecco’s
PBS without Ca, Mg or pH indicator (DPBS) and exposed to
1.17 M calcein-AM (Molecular Probes, Eugene, OR) for 45 min
at 37°C. After sequential washes, plates were scanned using a
Cytofluor 4000 (Applied Biosystems, Foster City, CA) with emis-
sion filters to detect calcein fluorescence.7 Cell numbers were also
determined by using a cell counter (Z1 counter, Beckman Coulter,
Miami, FL) to obtain an optimal ratio between fluorescence and
cell number.
Subendothelial matrix degradation
Preconfluent cultures of cloned endothelial cells were plated
into 4-well plates at an initial density of 2.0  105 cells/ml and
cultured in sulfate-free Fisher medium plus 4% dextran T-40 for
12 days. Na2[
35S]SO4 was then incubated at 50 Ci/ml for 72 hr
on day 5 after seeding without medium change. The subendothelial
ECM was exposed by dissolving the cell layer for 5 min at 25°C
with PBS containing 0.5% Triton X-100 and 20 mM NH4OH, then
washed 4 times with PBS.29 Melanoma cells (70W) were harvested
from subconfluent cultures and resuspended in DMEM/F-12 con-
taining 5% FBS. Cell suspensions (5  105 cells/ml) and 100 l
aliquots of DMEM/ F-12 containing either suramin or NF 127, NF
145 and NF 171 were placed at various concentrations on isolated
ECM and incubated for 24–72 hr at 37°C in a CO2 incubator.
Culture supernatants were withdrawn and centrifuged at 18,000g
for 10 min. The [35S]sulfate radioactivity released in the superna-
tant was analyzed by gel filtration on a Sepharose CL-6B column
(0.9  30 cm), as previously described.3,29,30 Radioactivity was
quantified on a liquid scintillation counter. Each experiment was
performed 3 times, and the variation of elution positions (Kav
values) did not exceed  15%. Controls to demonstrate hepara-
nase-type action (heparanase cleaves -glucuronosyl linkages at
HS intra-chain sites) were also performed. HS degradation prod-
ucts were tested for their susceptibility to heparinase, chondroiti-
nases ABC/AC and Flavobacterium heparitinases digestion
(Seikagaku America, St. Petersburg, FL).30
Preparation of heparanase-containing cellular extracts and
heparanase purification
Subconfluent 70W cells (2  108) were harvested and solubi-
lized in 50 mM Tris-HCl, pH 7.5, containing 1 mM phenylmeth-
ylsulfonyl fluoride (PMSF; Sigma Chemical Company, St. Louis,
MO), 5 mM N-ethylmaleimide (Sigma), 0.05% (w/v) sodium
azide, 0.5% (w/v) Triton X-100 at 4°C for 30 min. The cell extract
was centrifuged at 12,000g for 30 min at 4°C, and protein con-
centration was determined using the BCA protein assay protocol
(Pierce, Rockford, IL). The cellular extract (20–70 g of protein)
was then incubated in specific heparanase assays employing ra-
diolabeled HS substrates as described below.
Heparanase was purified as reported.9 Cellular extracts from
70W cells were loaded onto a heparin-Sepharose column (5.0  10
cm), washed in buffer containing 0.5 M NaCl and eluted in column
buffer containing 1.0 M NaCl. The eluate was then diluted with an
equal volume of dilution buffer 1 (50 mM sodium acetate, pH 6.0,
0.4% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfo-
nic acid or CHAPS). The heparin-Sepharose eluted fractions were
applied to a ConA-agarose column (2.5  10 cm) at a flow rate of
1 ml/min. The column was washed with ConA buffer (50 mM
sodium acetate, pH 6.0, 0.5 M NaCl, 0.2% CHAPS), and hepara-
nase was eluted with ConA buffer containing 0.7 M -methyl-
mannose. The eluate was concentrated and diluted with 5 volumes
of dilution buffer 2 (50 mM sodium acetate, pH 6.0, 0.2%
CHAPS), and ConA-agarose eluted fractions were applied to a
carboxy-methyl-Sepharose column (2.5  10 cm) at a flow rate of
1 ml/min. The column was washed with buffer (50 mM sodium
acetate, pH 6.5, 0.1–0.5 M NaCl, 0.2% CHAPS) and eluted with
a step gradient of NaCl from 0.1–0.5 M. Fractions containing
heparanase were collected, concentrated and mixed with an equal
volume of 5 M NaCl solution. The purified fractions from car-
boxymethyl-Sepharose were applied to a phenyl-Sepharose col-
umn (2.5  10 cm) equilibrated with phenyl buffer A (50 mM
Tris-HCl, 2.5 M NaCl, pH 7.3) and washed at a flow rate of 0.5
ml/min from 0–40 min. The heparanase was eluted with a gradient
of phenyl buffer B (50 mM Tris-HCl, 0.1% CHAPS, pH 7.3) from
0–100% over 100 min. The heparanase-containing fractions were
collected, concentrated and purity was visualized by silver-stained
SDS-PAGE. The concentration of protein was measured at various
purification steps by the BCA protein assay (Pierce).
Heparanase assay
Heparanase was assayed as previously described7,28,30 with
some modifications. Heparanase activity was determined by deg-
radation of [35S]HS using high-speed gel permeation column chro-
matography (HPLC).7,28 The heparan sulfate (HS) used was puri-
fied from the human cell line RL95. The purification, [35S] sulfate
radiolabeling, and use of cell-associated HS subpopulations from
RL95 cells has been previously reported.28 The molecular weight
of the specific HS subpopulations had a median value of 70,000
kDa as determined by agarose gel electrophoresis and Superose 6
chromatographic analysis using GAG chains of defined molecular
weight size as calibrating standards.28,29
Cellular extracts or purified heparanase from 70W cells were
incubated at 37°C with [35S]HS in 100 l of 50 mM sodium
acetate at pH 4.2. Reaction was terminated by adding 100 g of
heparin and by heating samples for 5 min at 100°C. The products
of [35S]HS yielded by heparanase reaction were analyzed by
HPLC analysis. Aliquots of the reaction were injected into a TSK
gel G3000 PWX2 column (7.8 mm 30 cm; 6 m particle size;
Toso Haas, Montgomeryville, PA) and run at 0.5 ml/min. Eluents
were collected and counted in a liquid scintillation counter.
Heparanase activity was determined by measuring the decrease of
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radioactivity in the first one-half area of intact [35S]HS peak
chromatogram.
Chemoinvasion assay
The invasive properties of melanoma 70W cells were assayed
by Transwell cell culture chambers and fluorescence plate scanner
analysis.7 Briefly, purified heparan sulfate proteoglycan (HSPG)
was applied to the filters (0.5 mg/ml). Alternatively, reconstituted
basement membrane (Matrigel™; BD Biosciences, Discovery Lab-
ware, Bedford, MA) was diluted 1:30 in cold DMEM/F12 without
phenol red and applied onto the upper surface of Transwell (6.5
mm diameter, 8 M pore size) polycarbonate filter inserts (Costar,
Cambridge, MA). The lower chamber contained a mixture of 0.5%
low-gelling agarose (FMC Bio Products, Rockland, ME), 0.5%
gelatin (Sigma) with addition of 10 nM of the chemotactic peptide
N-formyl-met-leu-phe (Sigma) and 25% phenol-red-free fresh mu-
rine brain endothelial cell-conditioned medium (MBE-CM, 48
hr).7 Cells suspended in serum-free, phenol-red-free DMEM/F-12
were seeded into the upper compartment at 2.0  104 cells/filter.
After 24 hr incubation at 37°C, the upper chambers were carefully
removed and the bottom chambers were treated with 1 M cal-
cein-AM for 1 hr at 37°C. After 4 washes with PBS, the plates
were analyzed for fluorescence using a computerized fluorescence
plate scanner system (Cytofluor 4000, Applied Biosystems, Foster
City, CA), and the formation of calcein was monitored by mea-
suring the increase in fluorescence at 530 nm (BB4 settings of
Cytofluor).
Fluorometric microculture cytotoxicity assay
A fluorometric microculture cytotoxicity assay (FMCA) proce-
dure was used to study the cytotoxicity of suramin-analogue com-
pounds. The FMCA is based on the measurement of fluorescence
generated from the hydrolysis of fluorescein diacetate (FDA) to
fluorescein by cells with intact plasma membranes and has been
previously described in detail.31 Briefly, 70W cells were resus-
pended in complete medium, and 180 l of cell suspension was
seeded into the wells of 96-well experimental microtitre plates.
The densities of the 70W cells were 5.0  103–2.0  104 cells/
well. Suramin and its analogues were tested in triplicate and at 5
different concentrations. Wells with cells but without compounds
served as controls and wells with only culture medium served as
blanks. The plates were subsequently incubated at 37°C in a
humidified atmosphere containing 5% CO2 for 72 hr. At the end of
the incubation period, the plates were centrifuged (800 g, 5 min)
and the medium was removed by aspiration. After 1 wash in PBS,
100 l/well of FDA (10 g/ml) dissolved in physiologic buffer
was added. The plates were then incubated for 30 min and the
generated fluorescence from each well was measured at 538 nm in
a 96-well scanning fluorometer. The fluorescence signal was found
to be proportional to the number of intact cells in the well. Quality
criteria for a successful analysis included a fluorescence signal in
the control wells of more than 5 the mean blank value and a
coefficient of variation in the control wells of  30%. A cell
survival index (SI) was subsequently derived and defined as the
fluorescence in the experimental wells compared to that in control
wells, with the blank values subtracted. IC30 values were deter-
mined as the concentration of compound giving an SI of 70%.
Encapsulation of bFGF-HSPG in alginate microspheres and in
vivo angiogenic assays
A method for the preparation and encapsulation of HSPG-bFGF
in alginate microspheres was used as described elsewhere.32
Briefly, HSPG-bFGF exposed to heparanase in presence or ab-
sence of suramin analogues was mixed with alginate gel (1.8%).
The mixture was used to prepare beads, at a volume of 10 ml, by
dropping them into a hardening solution of 1.5% CaCl2. After
polymerization, the alginate beads were extensively washed with
saline containing CaCl2 and stored at 4°C or used immediately.
The incorporation and release kinetics of compounds from alginate
beads were determined.33 In addition, alginate beads containing
the separate constituents (bFGF, HSPG-bFGF, suramin and
heparanase) were prepared and tested in rabbit ear chambers.
Alginate beads were implanted under general anesthesia (70
mg/kg ketamine and 10 mg/kg xylazine) in the ears of female New
Zealand white rabbits. For observations, the animals were sedated
by butorphanol and acepromazine (each at 1 mg/kg). The surgical
procedure and postoperative care was as previously described.34 A
low-power stereo microscope with a stage adjustment for viewing
the chambers was used for taking microphotographs at weekly
intervals. An angiogenic score was subsequently obtained by tri-
ple-blind evaluation of the microphotographs taken after analysis
of the chambers at weekly intervals. The following 4 parameters
were used: (i) the total area of the chamber covered by vessels; (ii)
the number of vessels originating from openings in the chambers;
(iii) the length of large anastomosing vessels; (iv) the number of
anastomosing vessels. The maximum numerical value for each
parameter was 10, adding to a maximal angiogenic score of 40 as
arbitrary units (AU).
RESULTS
Effects of suramin analogues NF 127, NF 145 and NF 171 on
heparanase activity
The purpose of our study was to analyze the effectiveness of
selected suramin analogues named NF 127, NF 145 and NF 171 to
inhibit heparanase activity and to relate it to suramin, a known
heparanase inhibitor.23 These compounds are napthalenetrisulfonic
acid derivatives of suramin and belong to a large category of
suramin analogues whose chemical structure, molecular weight,
and, more importantly, their capability to act as potent antiangio-
genic agents have been determined and reported.25–27 The ability
of 70W cells to degrade HS in the ECM was studied by allowing
the cells to interact with naturally produced sulfate-labeled ECM
followed by gel filtration analysis of degradation products released
into a culture medium.3,30 Degradation of HS in the ECM was
studied by incubation (72 hr at 37°C, pH 6.7) of high-heparanase-
containing 70W previously exposed to suramin or, alternatively, to
NF 127, NF 145 and NF 171 with a metabolically sulfate-labeled
ECM produced by cultured endothelial cells (MBE). Sulfate-la-
beled degradation products released into the incubation medium
were subjected to gel filtration on Sepharose-6B columns.3,30 In
the presence of the incubation medium alone, there was a constant
spontaneous release of labeled material consisting almost exclu-
sively ( 90%) of high-molecular-weight fragments eluted at or
next to V0 of the column.30 The proteolytic activity residing in the
ECM itself is responsible for the release of the high-molecular-
weight material. This nearly intact HSPG provides a soluble sub-
strate for subsequent degradation by heparanase.
Accumulation in the medium of low-molecular-weight, sulfate-
labeled degradation fragments was inhibited in the presence of
suramin analogues NF 127, NF 145 and NF 171 but not in their
absence (Fig. 1). Controls using suramin were performed because
melanoma heparanase is noncompetitively inhibited by suramin.23
That these HS degradative products were heparanase-digested was
confirmed by several control experiments demonstrating that they
were (i) 3–5-fold smaller than intact HS side chains;1,4,9 (ii)
released from the ECM by treatment with alkaline borohydride;30
and (iii) resistant to further digestion with chondroitinase ABC but
susceptible to deamination by nitrous acid.30
In a second set of experiments, heparanase purified from human
70W cells was incubated (24 hr at 37°C, pH 6.0) with sulfate-
labeled ECM in the absence or presence of increasing concentra-
tions of either suramin or NF 127, NF 145 and NF 171. Their
addition resulted in a corresponding decrease of heparanase activ-
ity to background levels at 100 M concentrations of compounds.
IC50 values for these analogues varied from 18–28 M, which was
consistently lower than the one observed for suramin (42 M; Fig.
2). Also, we performed heparanase assays by HPLC chromato-
graphic analysis of radiolabeled HS degradation products. When
radiolabeled HS was analyzed by HPLC, increased heparanase
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activity corresponded to the amount of 70W heparanase present in
the assay (data not shown). Conversely, in experiments where NF
127, NF 145 and NF 171 (or control suramin) were incubated with
purified heparanase, inhibition of its activity by specific hepara-
nase assays was observed (Table I).
Finally, the effects of suramin, NF 127, NF 145 and NF 171 on
70W cell growth viability were tested. In serum-free culture me-
dium supplemented with insulin and transferrin, the growth of
70W melanoma cells was not significantly affected by suramin or
related compounds at 100 M (Fig. 3) or at higher concentrations
of compounds (up to 200 M, data not shown).
Inhibition of melanoma cell invasion by suramin analogues NF
127, NF 145 and NF 171
The effect of NF 127, NF 145 and NF 171 on the in vitro
invasive capacity of brain-metastatic, high-heparanase-producing
70W cells was tested by seeding cells onto purified HSPG-coated
filters. Invasion assays were then performed through HSPG-coated
filters to determine whether heparanase production in 70W cells
could be blocked by these suramin analogues. The 70W cells were
treated with different concentrations of NF 127, NF 145 and NF
171, seeded on HSPG-coated filters and allowed to invade for 24
hr at 37°C. The results from 4 independent experiments indicated
that the invasion process was effectively inhibited by NF 127, NF
145, and NF 171 at 10 M (and higher) concentrations with a
significant decrease of invasive values found at a concentration of
compounds as low as 1.5 M. The results from these experiments
are shown in Table II.
In a second sets of experiments, invasion assays were performed
using the more commonly applied Matrigel™ as a coating barrier
on Transwell filters. Results from these experiments are included
for comparative purposes and confirmed inhibition of the invasion
process by suramin and the 3 suramin analogues tested (Table III).
Thirdly, a semiautomated in vitro fluorometric microculture
cytotoxicity assay (FMCA) was employed to evaluate the cytotox-
icity of the 3 suramin analogues using human 70W cells. In these
cells, NF 127, NF 145 and NF 171 exhibited comparable activities,
as mean IC30 values, to each other and to suramin (Table IV).
Inhibition of heparanase-induced angiogenesis by suramin
analogues NF 127, NF 145 and NF 171
Since the abilities of bFGF to bind ECM HSPG and to act as a
potent angiogenic factor have long been recognized,14,16 we have
evaluated the ability of NF 127, NF 145 and NF 171 to modulate
angiogenic heparanase activity in vivo by using the rabbit ear
chamber method. This in vivo angiogenic assay has been used for
the past 50 years as a well-controlled in vivo model to study
angiogenesis, wound healing and tissue responses.34 bFGF bound
to HSPG and encapsulated in alginate gel acts as a controlled
release delivery system.33 The encapsulation efficiency of alginate
microspheres was studied by using radioiodinated bFGF
([125I]bFGF) and comparing the amount of encapsulated bFGF
with that initially present in solution. [125I]bFGF release kinetics
were subsequently determined. A cumulative bFGF release into
0.15% saline at 37°C was noted over time, reaching 15–20% of
FIGURE 1 – Suramin analogues NF 127, NF 145 and NF 171 inhibit
heparanase activity expressed by human 70W melanoma cells. Human
70W melanoma cells (1  106/35 mm dish) were incubated (72 hr at
37°C, pH 6.7) on top of sulfate-labeled ECM, in absence (filled
squares) or presence of increasing concentrations of suramin (filled
triangles), NF 127 (open squares), NF 171 (filled diamonds) and NF
145 (open triangles). Sulfate-labeled degradation products released
into the incubation medium were analyzed by gel filtration on Sepha-
rose-6B column chromatography. Heparanase activity was expressed
as Kav  total cpm eluted in the peak (fractions 35–45) of the
column.30 One hundred percent values ranged from 2.7–3.0  104
cpm. Each experiment was performed 3 times, and the variation of
elution positions (Kav values) did not exceed  15%.
FIGURE 2 – Inhibition of purified 70W heparanase by NF 127, NF
145 and NF 171. Sulfate-labeled ECM was incubated (24 hr at 37°C,
pH 6.0) with purified preparations of human 70W heparanase (3.0
g/ml) in absence (filled squares) or in presence of increasing con-
centrations of NF 127 (open triangles), NF 171 (open squares), NF 145
(filled diamonds) and suramin (filled triangles). Sulfate-labeled deg-
radation products released into the incubation medium were analyzed
by gel filtration on Sepharose-6B column chromatography. Hepara-
nase activity is expressed as Kav  cpm eluted in the peak of the
column.30 Three independent experiments were performed confirming
the results shown.
TABLE I – INHIBITION OF 70W HEPARANASE ACTIVITY BY
SURAMIN ANALOGUES1
Compound Heparan sulfate degradation activity (Mean cpm  SD)
None added 13,409  420
 Suramin 6,978  342*
 NF 127 4,696  438*
 NF 145 3,828  705*
 NF 171 4,397  381*
1Purified heparanase was preincubated with suramin, NF 127, NF
145 and NF 171 (30 M for 24 hr at 37°C) then analyzed by specific
heparanase assays (see Material and Methods). Data shown represent
subtraction of control values (absence of heparanase in [35S]HS assay)
from data of test samples.–*p  0.01 for 4 separate experiments.
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growth factor release at 5–10 days, respectively, and a plateau of
30% at approximately 4 weeks (data not shown). Secondly, control
experiments were performed using alginate beads containing only
bFGF, HSPG-bFGF, suramin or heparanase, respectively, with
subsequent angiogenic score determination. Differential angio-
genic scores were obtained among the various constituents with
the highest values found in the presence of purified heparanase
(Fig. 4).
Implantation of HSPG-bFGF beads previously incubated with
purified heparanase, and in presence of suramin analogues, into
rabbit ear chambers produced a significantly decreased vascular-
ization. Photomicrographs were evaluated using several parame-
ters and an angiogenic score was obtained of significant value for
heparanase-induced angiogenesis in the presence of heparanase
(but without suramin or suramin analogues) with inhibition of the
enzyme in a dose-dependent manner in their presence. Represen-
tative experiments using NF 145, in our hands the most active
compound among the ones analyzed, are shown in Figure 5. When
heparanase-treated samples were analyzed, fine capillaries and
occasionally large vessels penetrated the chamber, covering almost
its entire surface (Fig. 5, lane 4). However, in the presence of NF
145, a distinct and significant difference in the degree and pattern
of vascularization was observed at NF 145 concentrations of 135
M and 180 M (Fig. 5, lane 3 and 2, respectively) until only a
limited capillary ingrowth was found at a 230 M concentration of
the drug (Fig. 5, lane 1).
Suramin and suramin analogues NF 127 and NF 171 were
similarly tested in rabbit ear chambers invasion assays. They
induced a statistically significant inhibition of heparanase-in-
duced angiogenic response (Table V). Using this assay, we
found suramin to have an IC50 value of 538 M. All 3 suramin
analogues possessed more potent inhibitory properties of
heparanase-induced angiogenesis compared to suramin, with
IC50 values ranging from 118 M for NF 145 to 181 M for NF
127 (Table V).
DISCUSSION
In our study, we have demonstrated that the suramin analogues
NF 127, NF 145 and NF 171 inhibited heparanase activity as well
as heparanase-induced ECM HS degradation and angiogenesis.
Specifically, heparanase inhibition by these compounds correlated
with decreased invasive capacity of human melanoma 70W cells
by in vitro invasion assays and decreased blood vessel formation
by in vivo angiogenic assays, thus linking the antiangiogenic
properties of NF 127, NF 145 and NF 171 with their ability to
inhibit heparanase.
Angiogenesis is a critical event in tumor cell metastasis because
the growth of solid tumors to a significant size depends upon
it.15,35,36 Therefore, angiogenic inhibitors have become an impor-
tant potential approach for cancer therapy. Heparanase is an HS-
specific endo--D-glucuronidase and a critical molecular determi-
nant of tumor metastasis because its activity directly correlates
with metastasis of tumor cells, being involved in their invasive-
ness.1–3,7–10
We and others have postulated 2 roles of heparanase in mela-
noma metastasis: One is that heparanase is relevant to the extrav-
asation of melanoma cells into secondary organs by degrading
subendothelial ECM HSPG degradation, whereas the second per-
tains to heparanase’s ability to release angiogenic factors, stored
within ECM HSPG, at the metastatic site and leading edge of
neovascularization. The mobilization of these factors and their
angiogenic stimulation is a critical event in angiogenesis.14–16
A number of studies have demonstrated that heparanase activity
and experimental metastasis are inhibited by nonanticoagulant and
low-molecular-weight species of heparin.2,6,37 It also has been
demonstrated that a variety of sulfated polysaccharides other than
heparin can inhibit heparanase and tumor growth.38–40 Finally, and
relevant to the purpose of our study, reports have documented
heparanase inhibition by suramin.7,23,40
Suramin, a polysulfonated naphthylurea, was originally devel-
oped as a trypanocidal agent.18,41 Results have been published
indicating that suramin is a useful antitumorigenic agent in human
malignancies.18 However, the clinical use of suramin has been
limited by its toxicity. The most serious adverse effect of suramin
use is the development of polyneuropathy, which ranges from
stocking-glove paresthesias to paralysis.42,43 To resolve this prob-
lem, suramin analogues have been developed with equivalent or
better antitumor activity and less toxicity.24,44
We hypothesized that some of these analogues could be effec-
tive antiheparanase agents. In particular, NF 127, NF 145 and NF
171 were chosen, among others, because they were proven to
possess a superior angiogenic inhibitory activity than suramin, and
for their structural similarities to suramin being naphtalenetrisul-
fonic acid derivatives.25–27 We examined the effect of these com-
pounds on melanoma cell heparanase and demonstrated that NF
127, NF 145 and NF 171 are more potent heparanase inhibitors
than suramin itself.
The mechanism(s) underlying antitumorigenic effects of
suramin and its analogues are poorly understood. It has been
postulated that they bind to growth factors, thus altering the
binding ability of growth factors to their respective recep-
tors.20,21,44 The enzymes involved in the catabolism of glycans,
such as ganglioside neuraminidase, -glucuronidase, hyaluroni-
dase and iduronate sulfatase, have also been found to be inhibited
by suramin, perhaps accounting for the aberrant accumulation of
sialogangliosides and glycosaminoglycans, including HS, derma-
tan sulfate and hyaluronic acid, in various organs of suramin-
treated patients and animals.18 Certainly, because heparanase is the
major endoglycosidase initiating the sequential cleavage of HS
linked to ECM HSPG, its inhibition is much more critical in tumor
metastasis than the inhibition of exoglycosidases and/or sulfatases.
FIGURE 3 – Effects of suramin and suramin analogues on 70W
melanoma cell growth. Human 70W cells (1  104) were seeded in
each well of 48-multiwell tissue culture plates and cultured in 0.5 ml
of DMEM/F-12 plus 5 g/ml insulin, 5 g/ml transferrin and 25 nM
sodium selenite in the absence (filled squares) or presence (100 M)
of NF 127 (open triangles), NF 171 (open squares), NF 145 (filled
diamonds) and suramin (filled triangles). Cell growth was monitored
by calcein-AM methodology using a Cytofluor 4000 (see Material and
Methods). Background fluorescence levels were determined and sub-
tracted to obtain specific fluorescence. Each point represents the av-
erage of triplicate determinations (SD  5%).
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We have considered that an alternative (or complementary)
mechanism of action of suramin analogues as anticancer agents in
general and antiangiogenic agents in particular is the inhibition of
ECM degradative enzymes like heparanase. The IC50 values for
NF 127, NF 145 and NF 171 were approximately one-third to
one-fourth of those seen for suramin, being valid for both inhibi-
tion of the enzyme and its angiogenic-related effects. Other en-
zymes and/or factors may be responsible for the antiangiogenic
properties of these compounds, whose inhibition capabilities and
mode of action may complement the ones seen for heparanase.
A trend that is emerging from studies involving suramin-like
compounds is that apart from sulfation or other negatively charged
moieties, there are no defined structural requirements for the
inhibition of heparanase activity. In general, this may explain why
diverse polyanionic molecules such as sulfated polysaccharides,40
phosphorothioate oligodeoxynucleotides,45 other synthetic poly-
carboxylic aromatic compounds,46 suramin23 or some of its ana-
logues as reported here all inhibit heparanase despite their different
molecular structure and chemical nature. The inhibition by such
unrelated polyanionic compounds indicates that both natural poly-
saccharides and synthetic polyanions may be applied as inhibitors
of tumor metastasis. However, it should be taken into account that
(i) not every polyanionic molecule is a good heparanase inhibitor
in vitro; (ii) not all heparanase-inhibiting molecules will efficiently
inhibit in vivo tumor cell invasion and angiogenesis; and (iii) a
number of small molecule inhibitors are currently being developed
that do not necessarily fit into the category of polyanionic com-
pounds. Certainly, the efficacy of a given molecule as an effective
in vivo inhibitor will have to depend on its pharmacokinetic
FIGURE 4 – Angiogenic scores of heparanase-induced angiogenesis.
Alginate beads containing encapsulated bFGF (lane 1), HSPG-bFGF
(lane 2), suramin (lane 3) or purified heparanase (lane 4) were intro-
duced into chambers and implanted in rabbit ears. At 35–45 days
post-implantation, the chambers were analyzed by light microscopy.
Photomicrographs (6–8 analyzed for each experiment) were evaluated
using 4 parameters (see Material and Methods). The maximum nu-
merical value for each parameter is 10, adding to a maximal angio-
genic score of 40 as arbitrary units (AU). Concentration of each
compound was approximately 40 ng/bead.
TABLE II – INHIBITION OF 70W MELANOMA CELL INVASION BY SURAMIN ANALOGUES: HSPG AS COATING BARRIER
Concentration
(M) Suramin NF 127 NF 145 NF 171
0 13.07  0.011 14.03  0.02 12.91  0.15 13.02  0.02
10 12.15  0.03** 11.36  0.03* 9.11  0.06** 9.89  0.02*
25 9.67  0.18** 8.69  0.06** 5.84  0.02** 3.51  0.02**
50 7.71  0.01** 2.81  0.01** 2.51  0.04*** 1.95  0.02**
100 0 0 0 0
200 0 0 0 0
n 	 32
170W arbitrary fluorescence units (AFU) at the end of incubation period (24 hr). AFU at time 0 were considered equal to 1.00.–2n, data
displayed are means of 3 independent experiments with quadruplicate assays performed in each experiment.–*p  0.005, **p  0.07, ***p 
0.001.
TABLE III – INHIBITION OF 70W MELANOMA CELL INVASION BY SURAMIN ANALOGUES: MATRIGEL™ AS COATING BARRIER
Concentration
(M) Suramin NF 127 NF 145 NF 171
0 9.41  0.011 10.38  0.04 8.77  0.03 9.37  0.30
10 8.26  0.02** 7.38  0.01* 6.83  0.05** 7.71  0.04**
25 6.77  0.03** 6.51  0.02** 4.14  0.01*** 2.42  0.03*
50 6.55  0.02* 4.49  0.03** 2.93  0.03* 2.08  0.01**
100 0 0 0 0
200 0 0 0 0
n 	 32
170W arbitrary fluorescence units (AFU) at the end of incubation period (24 hr). AFU at time 0 were considered equal to 1.00.–2n, data
displayed are means of 3 independent experiments with quadruplicate assays performed in each experiment.–*p  0.005, **p  0.05, ***p 
0.001.







1IC30 denotes compound concentration resulting in a survival index
of 70%. Shown are mean values of 3 independent experiments.
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properties (i.e., half-life in the circulation, mode of clearance) and
potential side effects.
In conclusion, we have demonstrated that 3 suramin analogues,
NF 127, NF 145 and NF 171, inhibit human heparanase and
heparanase-mediated angiogenesis. We believe that a part of the
antineoplastic effect of these drugs may be due to their heparanase
inhibitory action. Therefore, we postulate that heparanase can be
an important target (or one of the targets) of suramin analogues
involved in their mode of action in angiogenesis. Biochemical
pathways responsible for their antineoplastic and antiangiogenic
effects and the role of heparanase in these pathways will have to be
clarified. Our current findings support further investigations of the
possible usefulness of these and other suramin analogues, i.e.,
possessing different structural properties, as heparanase inhibitors
and therapeutic agents for metastatic disease.
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